ClinicalTrials.gg
CompletedNCT00627042Updated Oct 8, 2014Results posted

Study of IMC-1121B (Ramucirumab) in Participants With Liver Cancer Who Have Not Previously Been Treated With Chemotherapy

A Phase 2 interventional study of Ramucirumab (IMC-1121B) in Hepatocellular Carcinoma, sponsored by Eli Lilly and Company. Completed at 6 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-10-08.

Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
42
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies in Carcinoma, Hepatocellular by Eli Lilly and Company — none open to participants now, none under way, none of them phase 3. Carcinoma, Hepatocellular · Eli Lilly and Company.

Enrollment
8th of 13
42 · median 47
Started
2008
with 1 other
Phase 2
4 of 13
none open now
Registered
2nd of 13
by date

Among the 13 studies in Carcinoma, Hepatocellular by Eli Lilly and Company, this one is the 8th largest by enrollment, is one of 2 that started in 2008, is one of 4 in phase 2, and was the 2nd registered.

Carcinoma, Hepatocellular

3,651 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,063 are open to participants now.

Browse Carcinoma, Hepatocellular studies →

Open to participants now

None of the 13 studies in Carcinoma, Hepatocellular by Eli Lilly and Company is open now. The open studies under Carcinoma, Hepatocellular, anywhere →

Who these studies take

Of the 739 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 249 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 13 studies in Carcinoma, Hepatocellular by Eli Lilly and Company as a file.
02

Study summary

A study to determine how long ramucirumab (IMC-1121B) will stop cancer from growing in participants with liver cancer that cannot be treated with surgery.

Read the detailed description

Inhibition of angiogenesis is considered a promising approach to the treatment of cancer. Members of the vascular endothelial growth factor (VEGF) family and the VEGF receptor-2 (VEGFR-2) are important mediators of angiogenesis and are likely important therapeutic targets in advanced hepatocellular cancer (HCC).

Angiogenesis appears integral to HCC development and pathogenesis. Angiogenesis inhibition has been efficacious in both in vitro and in vivo HCC models and results of clinical studies also suggest potential to inhibit disease growth.

Ramucirumab is a fully human monoclonal antibody (MAb) that specifically binds to the extracellular domain of VEGFR-2 with high affinity. Phase 1 studies currently nearing completion have demonstrated safety and tolerability at clinically relevant doses, with preliminary evidence of clinical efficacy in a variety of human cancers.

03

Conditions studied

  • Hepatocellular Carcinoma

Keywords

  • Liver disease
  • Neoplasms
  • Liver neoplasms
  • Carcinoma, Hepatocellular
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The participant must have -confirmed, unresectable HCC
  • The participant has at least one unidimensionally-measurable target lesion [≥ 2 centimeters (cm) with conventional techniques, or ≥ 1 cm by spiral computed tomography (CT) or magnetic resonance imaging (MRI)], as defined by (RECIST). Target lesion(s) must not lay within a previously irradiated, ablated, or chemoembolized area. If a target lesion does lie in such an area, there must be evidence of growth on successive imaging studies, including tumor hypervascularity, in order for such a lesion to be considered a target lesion
  • The participant has a Cancer of the Liver Italian Programme (CLIP) score of 0-3
  • The participant has a Classification score of A or B (liver dysfunction)
  • The participant has provided signed

Exclusion criteria

Exclusion Criteria:

  • The participant has received prior systemic chemotherapy, biologic or anti-angiogenic therapy, or systemic therapy for HCC
  • The participant has had bleeding from esophageal or gastric varices during the 3 months prior to study participation. Note: If the participant has any history of known esophageal varices, or evidence of esophageal varices on CT/MRI, the participant must undergo endoscopic evaluation prior to study entry (minimally invasive capsule esophageal endoscopy is an acceptable initial modality). The participant with endoscopically detected esophageal varices is eligible provided he/she meets all other entry criteria. The participant with any history or current evidence of esophageal varices must receive oral beta-blocker therapy throughout participation while on study, he/she may receive optimal endoscopic therapy as determined by the consulting gastroenterologist or hepatologist, and must undergo regular endoscopic follow-up throughout participation while on study
  • The participant has acute hepatitis
  • The participant has central nervous system (CNS) or carcinomatous meningitis
  • The participant has poorly-controlled hypertension [in other words (ie), blood pressure in abnormal range despite medical management]
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
42 participants (actual)

Study arms

  • Experimental
    Ramucirumab (IMC-1121B)

    Biological: Ramucirumab (IMC-1121B)

Interventions

  • Participants will receive ramucirumab (IMC-1121B) at 8 milligrams per kilogram (mg/kg) administered over 1 hour every other week (every 14 days). Treatment will continue until there is evidence of disease progression, intolerable toxicity, or other withdrawal criteria are met.

    Also known as: Ramucirumab, IMC-1121B, LY3009806

06

What researchers measure

Primary outcomes

  1. Progression Free Survival (PFS) in Participants With Unresectable Hepatocellular Cancer Treated With the Monoclonal Antibody Ramucirumab

    PFS was defined as the time from the first day of therapy to the first evidence of disease progression or death from any cause. As classified according to Response Evaluation Criteria In Solid Tumors (RECIST) criteria, disease progression was having at least a 20% increase in the sum of the longest diameter of target lesions and/or unequivocal progression of a non-target lesion and/or detection of a new lesion. Participants who were alive and without disease progression and participants who did not progress and were subsequently lost to follow-up were censored at the last objective tumor assessment.

    Time frame: First dose to date of progressive disease or death due to any cause [every 3 cycles up to 18 months (1 cycle=2 weeks)]

Secondary outcomes

  1. Time to Progression

    The time from first day of therapy to the first date of objective evidence of progressive disease (PD) by Response Evaluation Criteria In Solid Tumors (RECIST) criteria. PD was defined as having at least a 20% increase in sum of longest diameter of target lesions and/or unequivocal progression of a non-target lesion and/or detection of new lesion. Time to PD was censored at the date of death or study discontinuation.

    Time frame: First dose to date of PD [every 3 cycles up to 18 months (1 cycle=2 weeks)]

  2. Overall Survival

    Overall survival (OS) was the duration from first dose to death due to any cause. OS was censored at last contact date for participants who were alive at the end of follow-up period or lost to follow-up.

    Time frame: First dose to death due to any cause up to 37.5 months

  3. Percentage of Participants With Complete Response or Partial Response (Objective Response Rate)

    Objective response rate (ORR) was defined as the percentage of participants with a confirmed best overall response of complete response (CR) or partial response (PR). As classified according to Response using Response Evaluation Criteria In Solid Tumors (RECIST) criteria, CR was the disappearance of all target and non-target lesions and any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 millimeters (mm) and normalization of tumor marker level of non-target lesions. PR was having at least a 30% decrease in sum of longest diameter of target lesions.

    Time frame: First dose to date of objective progressive disease (PD) or death up to 18 months

  4. Duration of Response

    Duration of response was the interval from the date of initial documented response \[complete response (CR) or partial response (PR)\] to the first documented date of disease progression, initiation of other (or additional) antitumor therapy was first reported, or death due to any cause. As classified according to Response Evaluation Criteria In Solid Tumors (RECIST) criteria, CR was the disappearance of all target lesions, PR was having at least a 30% decrease in the sum of the longest diameter of target lesions, and disease progression was having at least a 20% increase in the sum of the longest diameter of target lesions and/or unequivocal progression of a non-target lesion and/or detection of a new lesion. Data were censored for participants who did not progress or die.

    Time frame: Time of first response (CR or PR) to disease progression, or death due to any cause [every 3 cycles up to 18 months (1 cycle=2 weeks)]

  5. Number of Participants With Serum Anti-Ramucirumab Antibodies

    Time frame: Prior to dosing at baseline, Cycles 4 and 7, and 30 days after end of therapy (1 cycle=2 weeks)

  6. Number of Participants With Drug-Related Treatment-Emergent Adverse Events

    Data presented are the number of participants who experienced treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), Grade 3 or higher TEAEs, or adverse events (AEs) leading to discontinuation of treatment that were considered by the investigator to be related to ramucirumab. A summary of SAEs and other nonserious AEs, regardless of causality, is located in the Reported Adverse Events section.

    Time frame: First dose to 37.5 months

07

Results

Posted Jul 3, 2014
Limitations and caveats
The duration of response results should be interpreted with caution since the sample size for this analysis was very small (2 participants).

Participant flow

Participant flow — Overall Study
MilestoneRamucirumab (IMC-1121B)
Started42
Received at least 1 dose of study drug42
Completed40
Not completed2
Withdrew: Withdrawal by subject2

Outcome measures

PrimaryProgression Free Survival (PFS) in Participants With Unresectable Hepatocellular Cancer Treated With the Monoclonal Antibody Ramucirumab

PFS was defined as the time from the first day of therapy to the first evidence of disease progression or death from any cause. As classified according to Response Evaluation Criteria In Solid Tumors (RECIST) criteria, disease progression was having at least a 20% increase in the sum of the longest diameter of target lesions and/or unequivocal progression of a non-target lesion and/or detection of a new lesion. Participants who were alive and without disease progression and participants who did not progress and were subsequently lost to follow-up were censored at the last objective tumor assessment.

Time frame:
First dose to date of progressive disease or death due to any cause [every 3 cycles up to 18 months (1 cycle=2 weeks)]
Reported as:
Median · months
Progression Free Survival (PFS) in Participants With Unresectable Hepatocellular Cancer Treated With the Monoclonal Antibody Ramucirumab
monthsRamucirumab (IMC-1121B)
Progression Free Survival (PFS) in Participants With Unresectable Hepatocellular Cancer Treated With the Monoclonal Antibody Ramucirumab4.0 (2.6 to 5.7)
SecondaryTime to Progression

The time from first day of therapy to the first date of objective evidence of progressive disease (PD) by Response Evaluation Criteria In Solid Tumors (RECIST) criteria. PD was defined as having at least a 20% increase in sum of longest diameter of target lesions and/or unequivocal progression of a non-target lesion and/or detection of new lesion. Time to PD was censored at the date of death or study discontinuation.

Time frame:
First dose to date of PD [every 3 cycles up to 18 months (1 cycle=2 weeks)]
Reported as:
Median · months
Time to Progression
monthsRamucirumab (IMC-1121B)
Time to Progression4.2 (2.8 to 8.4)
SecondaryOverall Survival

Overall survival (OS) was the duration from first dose to death due to any cause. OS was censored at last contact date for participants who were alive at the end of follow-up period or lost to follow-up.

Time frame:
First dose to death due to any cause up to 37.5 months
Reported as:
Median · months
Overall Survival
monthsRamucirumab (IMC-1121B)
Overall Survival12.0 (6.1 to 19.7)
SecondaryPercentage of Participants With Complete Response or Partial Response (Objective Response Rate)

Objective response rate (ORR) was defined as the percentage of participants with a confirmed best overall response of complete response (CR) or partial response (PR). As classified according to Response using Response Evaluation Criteria In Solid Tumors (RECIST) criteria, CR was the disappearance of all target and non-target lesions and any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 millimeters (mm) and normalization of tumor marker level of non-target lesions. PR was having at least a 30% decrease in sum of longest diameter of target lesions.

Time frame:
First dose to date of objective progressive disease (PD) or death up to 18 months
Reported as:
Number · percentage of participants
Percentage of Participants With Complete Response or Partial Response (Objective Response Rate)
percentage of participantsRamucirumab (IMC-1121B)
Percentage of Participants With Complete Response or Partial Response (Objective Response Rate)9.5 (2.7 to 22.6)
SecondaryDuration of Response

Duration of response was the interval from the date of initial documented response \[complete response (CR) or partial response (PR)\] to the first documented date of disease progression, initiation of other (or additional) antitumor therapy was first reported, or death due to any cause. As classified according to Response Evaluation Criteria In Solid Tumors (RECIST) criteria, CR was the disappearance of all target lesions, PR was having at least a 30% decrease in the sum of the longest diameter of target lesions, and disease progression was having at least a 20% increase in the sum of the longest diameter of target lesions and/or unequivocal progression of a non-target lesion and/or detection of a new lesion. Data were censored for participants who did not progress or die.

Time frame:
Time of first response (CR or PR) to disease progression, or death due to any cause [every 3 cycles up to 18 months (1 cycle=2 weeks)]
Reported as:
Median · months
Duration of Response
monthsRamucirumab (IMC-1121B)
Duration of Response14.1 (4.3 to 14.1)
SecondaryNumber of Participants With Serum Anti-Ramucirumab Antibodies
Time frame:
Prior to dosing at baseline, Cycles 4 and 7, and 30 days after end of therapy (1 cycle=2 weeks)
Reported as:
Number · participants
Number of Participants With Serum Anti-Ramucirumab Antibodies
participantsRamucirumab (IMC-1121B)
Number of Participants With Serum Anti-Ramucirumab Antibodies6
SecondaryNumber of Participants With Drug-Related Treatment-Emergent Adverse Events

Data presented are the number of participants who experienced treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), Grade 3 or higher TEAEs, or adverse events (AEs) leading to discontinuation of treatment that were considered by the investigator to be related to ramucirumab. A summary of SAEs and other nonserious AEs, regardless of causality, is located in the Reported Adverse Events section.

Time frame:
First dose to 37.5 months
Reported as:
Number · participants
Number of Participants With Drug-Related Treatment-Emergent Adverse Events
participantsRamucirumab (IMC-1121B)
Related TEAE41
Related SAE9
Related Grade 3 or higher TEAE14
Related AE leading to discontinuation6

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ramucirumab (IMC-1121B)—24/42 (57.1%)41/42 (97.6%)
Most frequent serious events
Showing 10 of 39
Most frequent serious events
EventRamucirumab (IMC-1121B)
GASTROINTESTINAL HAEMORRHAGEGastrointestinal disorders3/42
HYPERTENSIONVascular disorders3/42
ASCITESGastrointestinal disorders2/42
FATIGUEGeneral disorders2/42
INFUSION RELATED REACTIONGeneral disorders2/42
PYREXIAGeneral disorders2/42
PNEUMONIAInfections and infestations2/42
CONFUSIONAL STATEPsychiatric disorders2/42
HYPOXIARespiratory, thoracic and mediastinal disorders2/42
ADRENAL INSUFFICIENCYEndocrine disorders1/42
Most frequent other events
Showing 10 of 36
Most frequent other events
EventRamucirumab (IMC-1121B)
FATIGUEGeneral disorders28/42
HEADACHENervous system disorders16/42
HYPERTENSIONVascular disorders16/42
NAUSEAGastrointestinal disorders15/42
DIARRHOEAGastrointestinal disorders14/42
OEDEMA PERIPHERALGeneral disorders14/42
ANOREXIAMetabolism and nutrition disorders11/42
ABDOMINAL DISTENSIONGastrointestinal disorders8/42
ABDOMINAL PAINGastrointestinal disorders8/42
WEIGHT DECREASEDInvestigations8/42

Baseline characteristics

Participants who received at least 1 dose of ramucirumab.

Age, Customized
Age, Customized(participants)Ramucirumab (IMC-1121B)
Between 18 and 65 years27 ± 10.70
>=65 years15
Sex: Female, Male
Sex: Female, Male(Participants)Ramucirumab (IMC-1121B)
Female8
Male34
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Ramucirumab (IMC-1121B)
Hispanic or Latino3
Not Hispanic or Latino39
Unknown or Not Reported0
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Ramucirumab (IMC-1121B)
American Indian or Alaska Native1
Asian4
Native Hawaiian or Other Pacific Islander0
Black or African American2
White32
Race Other: Hispanic1
Race Other: Black and Asian1
Race Other: Greek1
Region of Enrollment
Region of Enrollment(participants)Ramucirumab (IMC-1121B)
United States42
Child-Pugh Score
Child-Pugh Score(participants)Ramucirumab (IMC-1121B)
A31
B11
Barcelona Stage
Barcelona Stage(participants)Ramucirumab (IMC-1121B)
A2
B4
C36
Macrovascular Invasion
Macrovascular Invasion(participants)Ramucirumab (IMC-1121B)
Present7
Absent32
Not Available2
Missing1

2 further baseline measures are reported on the registry.

08

Study locations

6 sites
  • ImClone Investigational Site
    Los Angeles, California 90095, United States
  • ImClone Investigational Site
    Chicago, Illinois 60611, United States
  • ImClone Investigational Site
    Metairie, Louisiana 70006, United States
  • ImClone Investigational Site
    Boston, Massachusetts 02114, United States
  • ImClone Investigational Site
    Burlington, Massachusetts 01805, United States
  • ImClone Investigational Site
    Philadelphia, Pennsylvania 19104, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2008, a primary completion of May 2011 and a completion of May 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2014, 3 years 2 months after primary completion. A results delay was requested in Aug 2010.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 18, 2008
First posted
Feb 29, 2008
Start
Feb 2008
Primary completionActual
May 2011
CompletionActual
May 2011
Results delay requested
Aug 25, 2010
Results first posted
Jul 3, 2014
Last update
Oct 8, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 8, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00627042
Responsible party
Sponsor
First posted
Feb 29, 2008
Start date
Feb 2008
Primary completion
May 2011
Completion
May 2011
Results posted
Jul 3, 2014
Last update
Oct 8, 2014

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ramucirumab

Start the discussion